

## Apixaban

## Section

Medicines affecting coagulation

## Indications

Therapeutic equivalent to dabigatran pour

Venous thromboembolism

Therapeutic equivalent to dabigatran pour

Other specified atrial fibrillation

## Cyanocobalamin

## Section

Antianaemia medicines

## Indications

Anaemias or other erythrocyte disorders

## Dabigatran

## Section

Medicines affecting coagulation

Oral &gt; Solid: 110 mg; 150 mg

## Indications

Venous thromboembolism

Other specified atrial fibrillation

## Dalteparin

## Section

Medicines affecting coagulation

## Indications

Therapeutic equivalent to enoxaparin pour

Acute ischaemic heart disease

Therapeutic equivalent to enoxaparin pour

Venous thromboembolism

## Darbepoetin alfa

## Section

Antianaemia medicines

## Indications

Therapeutic equivalent to erythropoiesis-stimulating agents pour

Anaemia due to chronic disease

## Deferasirox

### Section

Other medicines for haemoglobinopathies

Oral > Solid > dispersible tablet: 100 mg; 125 mg; 250 mg; 400 mg; 500 mg

Oral > Solid > tablet: 90 mg; 180 mg; 360 mg

### Indications

Other specified sickle cell disorders or other haemoglobinopathies

Thalassaemias

Therapeutic equivalent to [deferroxamine](#) pour

Thalassaemias

## Deferiprone

### Section

Other medicines for haemoglobinopathies

### Indications

Therapeutic equivalent to [deferasirox](#) pour

Other specified sickle cell disorders or other haemoglobinopathies

Therapeutic equivalent to [deferasirox](#) pour

Thalassaemias

## Deferoxamine

### Section

Other medicines for haemoglobinopathies

Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)

### Indications

Other specified sickle cell disorders or other haemoglobinopathies

Thalassaemias

## Desmopressin

### Section

Medicines affecting coagulation

Parenteral > General injections > IV: 4 µg per mL in 1 mL ampoule (acetate)

Local > Nasal > Spray: 10 µg per dose (acetate)

### Indications

Haemophilia A

Von Willebrand disease

## Edoxaban

### Section

Medicines affecting coagulation

### Indications

Therapeutic equivalent to [dabigatran](#) pour

Venous thromboembolism

Therapeutic equivalent to [dabigatran](#) pour

Other specified atrial fibrillation

## Enoxaparin

### Section

#### Medicines affecting coagulation

Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule

### Indications

Acute ischaemic heart disease

Venous thromboembolism

## Epoetin alfa

### Section

#### Antianaemia medicines

### Indications

Therapeutic equivalent to erythropoiesis-stimulating agents pour

Anaemia due to chronic disease

## Epoetin beta

### Section

#### Antianaemia medicines

### Indications

Therapeutic equivalent to erythropoiesis-stimulating agents pour

Anaemia due to chronic disease

## Epoetin theta

### Section

#### Antianaemia medicines

### Indications

Therapeutic equivalent to erythropoiesis-stimulating agents pour

Anaemia due to chronic disease

## Erythropoiesis-stimulating agents

### Section

#### Antianaemia medicines

Parenteral > General injections > unspecified: 1000 IU per 0.5 mL pre-filled syringe; 2000 IU per 0.5 mL pre-filled syringe; 3000 IU per 0.3 mL pre-filled syringe; 4000 IU per 0.4 mL pre-filled syringe; 5000 IU per 0.5 mL pre-filled syringe; 6000 IU per 0.6 mL pre-filled syringe; 8000 IU per 0.8 mL pre-filled syringe; 10000 IU per 1 mL pre-filled syringe; 20000 IU per 0.5 mL pre-filled syringe; 40000 IU per 1 mL pre-filled syringe

### Indications

Anaemia due to chronic disease

## Ferrous salt

### Section

#### Antianaemia medicines

Oral > Liquid: 25 mg per mL iron (as sulfate)

Oral > Solid: 60 mg iron

### Indications

Iron deficiency anaemia

## Ferrous salt + folic acid

### Section

#### Antianaemia medicines

Oral > Solid: 60 mg iron + 2.8 mg

Oral > Solid > tablet: 60 mg elemental iron + 400 µg tablet; 60 mg elemental iron + 2.8 mg

### Indications

Iron deficiency anaemia

Clefts of lip, alveolus or palate

Iron deficiency anaemia

Anencephaly or similar anomalies

Spina bifida

## Folic acid

### Section

#### Antianaemia medicines

Oral > Solid: 1 mg tablet; 5 mg tablet

Oral > Solid: 400 µg

### Indications

Folate deficiency anaemia

Anencephaly or similar anomalies

Spina bifida

Cephalocele

## Heparin sodium

### Section

#### Medicines affecting coagulation

Parenteral > General injections > IV: 1000 IU per mL in 1 mL ampoule; 20000 IU per mL in 1 mL ampoule; 5000 IU per mL in 1 mL ampoule

### Indications

Venous thromboembolism

Unstable angina

Acute ischaemic heart disease

## Hydroxocobalamin

### Section

#### Antianaemia medicines

Parenteral > General injections > IM: 1 mg per mL in 1 mL ampoule (as acetate); 1 mg per mL in 1 mL ampoule (as hydrochloride); 1 mg per mL in 1 mL ampoule (as sulfate)

### Indications

Megaloblastic anaemia due to vitamin B12 deficiency

## Hydroxycarbamide (hydroxyurea)

### Section

Other medicines for haemoglobinopathies

Oral > Solid > dosage form: 200 mg; 500 mg; 1 g; 100 mg

### Indications

Other specified sickle cell disorders or other haemoglobinopathies

## Methoxy polyethylene glycol-epoetin beta

### Section

Antianaemia medicines

### Indications

Therapeutic equivalent to erythropoiesis-stimulating agents pour

Anaemia due to chronic disease

## Nadroparin

### Section

Medicines affecting coagulation

### Indications

Therapeutic equivalent to enoxaparin pour

Acute ischaemic heart disease

Therapeutic equivalent to enoxaparin pour

Venous thromboembolism

## Phytomenadione

### Section

Medicines affecting coagulation

Parenteral > General injections > IV: 10 mg per mL in ampoule; 1 mg per mL in ampoule

Oral > Solid: 10 mg tablet

### Indications

Haemorrhagic disorder due to other specified circulating anticoagulants

Haemorrhagic or haematological disorders of fetus or newborn

## Protamine sulfate

### Section

Medicines affecting coagulation

Parenteral > General injections > IV: 10 mg per mL in 5 mL ampoule

### Indications

Haemorrhagic disorder due to other specified circulating anticoagulants

## Rivaroxaban

### Section

Medicines affecting coagulation

### Indications

Therapeutic equivalent to dabigatran pour

Venous thromboembolism

Therapeutic equivalent to dabigatran pour

Other specified atrial fibrillation

## Tranexamic acid

### Section

Medicines affecting coagulation

Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule

### Indications

Haemorrhage, not elsewhere classified

## Warfarin

### Section

Medicines affecting coagulation

Oral > Solid: 5 mg (sodium salt); 1 mg (sodium salt); 2 mg (sodium salt);  
0.5 mg (sodium salt)

### Indications

Other specified diseases of arteries or arterioles

Cerebral ischaemic stroke due to embolic occlusion

Venous thromboembolism

Atrial fibrillation